Nicholas Grund's most recent trade in Akebia Therapeutics Inc. was a trade of 53,585 Common Stock done at an average price of $1.4 . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 02 Feb 2026 | 53,585 | 592,994 (0%) | 0% | 1.4 | 74,483 | Common Stock |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 02 Feb 2026 | 31,244 | 561,750 (0%) | 0% | 1.4 | 43,429 | Common Stock |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 320,000 | 320,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 204,000 | 646,579 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 292,300 | 292,300 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 194,900 | 498,200 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 2.10 per share. | 31 Jan 2025 | 55,621 | 442,579 (0%) | 0% | 2.1 | 116,804 | Common Stock |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 454,950 | 454,950 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 303,300 | 303,300 (0%) | 0% | 0 | Common Stock |